SVEP1-based peptide

SVEP1-based peptide is a 9-amino-acid peptide derived from the extracellular matrix protein SVEP1 (Sushi, von Willebrand factor type A, EGF, and pentraxin domain-containing protein 1). Developed by researchers at Tel Aviv University, the peptide acts as a competitive antagonist of the integrin α9β1 receptor, which is highly expressed on pro-inflammatory adipose tissue macrophages. By blocking the interaction between SVEP1 and integrin α9β1, the peptide inhibits macrophage adhesion, migration, and activation, thereby suppressing MAPK and NF-κB inflammatory pathways. In preclinical models of diet-induced obesity, local administration of the peptide reduces adipose tissue inflammation, improves glucose tolerance and insulin sensitivity, and alleviates hepatic dysfunction, making it a potential therapeutic candidate for obesity-induced adipose tissue dysfunction and type 2 diabetes.

Other names

SVEP1 peptideSVEP-1 peptideSVEP 1 peptideSVEP1-derived peptideSVEP-1-derived peptideSVEP 1-derived peptide